Episode 4: Keeping Up in the New Era of Cancer Care

Our VP of market strategy shares her insights with Becker's Hospital Review.

Our associate CMO writes in ASCO Post about an often-overlooked skill.

Our CMO Dr. Monica Soni, and American Cancer Society's Chief Patient Officer Dr. Arif Kamal discuss current challenges and the future of effective palliative care.

Our associate CMO writes for the ASCO Post about the lessons she learned from a loved one's experience with terminal cancer.

Our chief medical officer speaks with Managed Healthcare Executive about the financial toxicity of cancer treatment.

Treating patients the same isn't always the path to improved outcomes, writes our associate chief medical officer.

Our associate chief medical officer writes in STAT on the need for greater transparency by physicians.

New Century Health and Humana's national partnership improves patient experience and eases administrative burdens on provider practices.

How do social determinants of health impact outcomes in cancer care? New Century Health Associate CMO Dr. Monica Soni and Radiation Oncologist Dr. Onyinye Balogun discuss.

New Century Health and our Vital Decisions solution seek to ensure more cancer patients receive end-of-life care that aligns with their wishes.

NCH’s high-value clinical oncology pathways, patient triage programs and provider engagement strategies help community practice to succeed in value-based payment program.

The predicted wave of late-stage cancers is taking longer to materialize than we expected.

Our associate chief medical officer shares her insights with the American Journal of Managed Care's podcast.

Which components of the recently announced Cancer Moonshot should get high priority for the initiative to succeed? Our chief medical officer, Dr. Andrew Hertler, outlines three key questions to track.

New Century Health Associate Chief Medical Officer Monica Soni explores health inequities in cancer cares and shares strategies for how to address them.

Dr. Andrew Hertler explains three key criteria for evaluating fast-tracked drugs.

Red flags cause clinical reviewers to question a radiation oncologist’s diagnosis.

Health plan clinical leaders joined us for an insightful discussion on the path toward high-value cancer care.

Home-based chemotherapy infusions may offer convenience but also raise a host of questions.

Discussing drug costs should be a core tenet of shared decision-making.